Editas Medicine to Present Groundbreaking Gene Editing Medicine at American Heart Association Scientific Sessions 2025

Strategic Insights -

Editas Medicine, a pioneering gene editing company, will present a digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025, showcasing its transformative LDL cholesterol-lowering in vivo CRISPR gene editing medicine. The presentation, titled "A transformative LDL cholesterol-lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates," will highlight the medicine's potential to upregulate the LDL receptor in mice and non-human primates, leading to reduced LDL cholesterol levels. This innovative approach has the potential to revolutionize the treatment of high cholesterol, a major risk factor for heart disease.

Key Takeaways:

  • Editas Medicine will present a digital poster presentation at the American Heart Association (AHA) Scientific Sessions 2025, highlighting its transformative LDL cholesterol-lowering in vivo CRISPR gene editing medicine.
  • The medicine, which functionally upregulates the LDL receptor in mice and non-human primates, has shown promising results in reducing LDL cholesterol levels.
  • The presentation will take place on Saturday, November 8, from 10:45 a.m. to 11:45 a.m. CT, in the Basic Science Zone.
  • Editas Medicine is focused on developing transformative in vivo medicines for serious diseases, including those related to cardiovascular health.
  • The company has established partnerships with prestigious institutions, including the Broad Institute and Harvard University, to advance its gene editing technology.

Statistics:

  • The American Heart Association (AHA) Scientific Sessions 2025 will take place from November 7-10 in New Orleans, Louisiana.
  • Editas Medicine's digital poster presentation will be available on the company's website at the time of the presentation and will remain accessible following the event.
  • The company is an exclusive licensee of the Cas12a patent estate and Broad Institute's Cas9 patent estates for human medicines.

Sources:

  • GlobeNewswire: "Editas Medicine to Present at American Heart Association Scientific Sessions 2025"
  • Editas Medicine: "About Editas Medicine"
  • Broad Institute: "Cas9 Patent Estate"
  • American Heart Association: "Scientific Sessions 2025"